Key Takeaways
- A new collaboration between Novo Nordisk and Hims & Hers will enable obesity medication sales through the telehealth platform, with an announcement expected Monday
- After-hours trading saw Hims shares skyrocket 39% on the partnership news
- This agreement resolves ongoing litigation, including a patent violation case Novo initiated last month
- A previous partnership between the companies collapsed due to disagreements about marketing approaches and compounded drug distribution
- Federal regulators had warned Hims about potential enforcement regarding its $49 generic semaglutide offering
A significant partnership is taking shape between Novo Nordisk and Hims & Hers, bringing obesity medications to the telehealth company’s platform and putting an end to their contentious legal battle that had intensified into patent litigation mere weeks earlier.
The arrangement was initially disclosed by Bloomberg News on Friday, based on information from an anonymous source. The announcement triggered a dramatic 39% surge in Hims shares during extended trading hours.
Novo Nordisk A/S, NVO
Both organizations are preparing for an official public announcement potentially arriving Monday. Details regarding the financial structure of this partnership remain undisclosed.
Dramatic Shift From Legal Battle to Business Alliance
The reversal is remarkable. Merely a month ago, Novo initiated patent infringement proceedings against Hims following the telehealth firm’s introduction — and subsequent withdrawal — of a $49 compounded alternative to Novo’s weight loss medication.
Federal health authorities had also issued warnings about possible enforcement action against Hims concerning its distribution of compounded semaglutide, the primary compound found in both Wegovy and Ozempic.
The combination of regulatory scrutiny and Novo’s legal offensive created significant challenges for Hims entering the current week.
This marks the second collaboration attempt between these companies. Novo terminated their initial partnership last year, expressing concerns about Hims’ promotional methods and its ongoing distribution of generic Wegovy alternatives.
The fresh agreement signals a renewed collaboration effort, seemingly built on mutually acceptable conditions.
Strategic Implications for Both Organizations
For Novo, this alliance provides an additional avenue to distribute its branded weight-loss medications amid intensifying competition within the obesity pharmaceutical sector.
A representative from Novo stated the organization maintains “ongoing discussions with companies that can help improve patient access to FDA-approved medicines.” The company has provided limited additional public commentary.
Hims declined to provide comments prior to publication.
For Hims, this partnership represents a strategic shift. The telehealth company had been emphasizing compounded semaglutide as an affordable substitute for Novo’s premium-priced medications.
That approach encountered obstacles after the FDA removed semaglutide from its shortage list earlier this year, essentially eliminating the regulatory justification for compounding facilities to continue production.
Current Market Status
Hims shares climbed 39% during Friday’s after-hours session. Throughout standard trading hours, both NVO and HIMS finished lower — NVO declining 1.25% while HIMS dropped 0.88%.
The official partnership announcement is anticipated to arrive Monday, March 9 at the earliest.
The post Hims & Hers (HIMS) Stock Soars 39% on Novo Nordisk (NVO) Obesity Drug Partnership appeared first on Blockonomi.
Source: https://blockonomi.com/hims-hers-hims-stock-soars-39-on-novo-nordisk-nvo-obesity-drug-partnership/